ストックスクリーナーアプリを入手
5.53
1.65%
0.09
アフターアワーズ：
5.60
0.07
+1.27%
前日終値:
$5.44
開ける：
$5.61
24時間の取引高:
6.79M
Relative Volume:
1.10
時価総額：
$1.69B
収益：
$79.21M
当期純損益:
$-143.96M
株価収益率:
-11.53
EPS:
-0.4796
ネットキャッシュフロー:
$-189.60M
1週間 パフォーマンス:
+4.93%
1か月 パフォーマンス:
+32.93%
6か月 パフォーマンス:
+56.66%
1年 パフォーマンス:
+59.37%
1日の値動き範囲:
$5.3301
$5.7399
1週間の範囲:
$5.01
$5.76
52週間の値動き範囲:
$2.745
$6.79
Abcellera Biologics Inc Stock (ABCL) Company Profile
Compare ABCL vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
5.53 | 1.69B | 79.21M | -143.96M | -189.60M | -0.4796 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-07-07 | 再開されました | Leerink Partners | Outperform |
| 2024-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2024-02-22 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-12-05 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2023-10-13 | 再開されました | Piper Sandler | Overweight |
| 2023-02-28 | 開始されました | Cowen | Outperform |
| 2022-12-15 | 開始されました | Goldman | Buy |
| 2022-11-16 | 開始されました | Truist | Buy |
| 2021-12-21 | 開始されました | The Benchmark Company | Buy |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2021-01-05 | 開始されました | Berenberg | Buy |
| 2021-01-05 | 開始されました | Credit Suisse | Outperform |
| 2021-01-05 | 開始されました | SVB Leerink | Outperform |
| 2021-01-05 | 開始されました | Stifel | Buy |
すべてを表示
Abcellera Biologics Inc (ABCL) 最新ニュース
Abcellera Biologics Inc (ABCL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Abcellera Biologics Inc (ABCL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Abcellera Biologics Inc (ABCL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies - TradingView
A potential billion-dollar deal looks for new ways to beat back cancer - The Business Journals
ABCL and Jazz Pharmaceuticals Enter Collaboration for T-Cell Eng - GuruFocus
Is ABCELLERA BIOLG (ABCL) Outperforming Other Medical Stocks This Year? - MSN
AbCellera (ABCL) Partners with Jazz Pharmaceuticals for Cancer R - GuruFocus
AbCellera, Jazz Partner on Next-Generation Cancer Antibodies - TipRanks
AbCellera (NASDAQ: ABCL) inks Jazz cancer antibody pact with $56M upfront, big milestones - Stock Titan
Jazz taps Abcellera in potential $4B antibody discovery deal - BioWorld News
Jazz Pharmaceuticals, AbCellera announce oncology deal - grafa.com
Jazz, AbCellera in deal to develop T-cell engaging multispecific antibodies - MSN
Jazz Pharmaceuticals, AbCellera partner on cancer antibodies By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals, AbCellera partner on cancer antibodies - Investing.com UK
Jazz Pharmaceuticals (JAZZ) Partners with AbCellera for $848M An - GuruFocus
Jazz Pharmaceuticals plc And AbCellera Biologics Inc Announces Collaboration To Discover Next-Generation T-Cell Engaging Multispecific Antibodies - marketscreener.com
Jazz Pharmaceuticals, AbCellera Biologics to Collaborate on T-cell Engaging Multispecific Antibodies - marketscreener.com
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies - PR Newswire
AbCellera: An AI-Era Antibody Platform Trading For Little More Than Its Cash (NASDAQ:ABCL) - Seeking Alpha
Abcellera Biologics Inc (ABCL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Abcellera Biologics Inc (ABCL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Abcellera Biologics Inc (ABCL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Abcellera Biologics Inc (ABCL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Abcellera Biologics Inc (ABCL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Abcellera Biologics Inc (ABCL) Institutional Confidence - TradingKey
ABCL - Finviz
AbCellera Biologics shareholders approve director elections and auditor at annual meeting - Investing.com
Is AbCellera (ABCL) Using Boardroom Oncology Talent to Redefine Its Clinical Ambitions? - simplywall.st
AbCellera Biologics (ABCL) grants director 111,701 share options - Stock Titan
AbCellera (ABCL) director Stephen Quake awarded 111,701 share options - Stock Titan
AbCellera (ABCL) director receives 111,701 share options grant - Stock Titan
AbCellera (NASDAQ: ABCL) shareholders back directors, auditor and Say-on-Pay - Stock Titan
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - MSN
AbCellera (ABCL) director Sandor Victor reports initial insider status on Form 3 - Stock Titan
Wall Street Analysts Think ABCELLERA BIOLG (ABCL) Could Surge 85.59%: Read This Before Placing a Bet - MSN
AbCellera Biologics(ABCL) Stock Options Chain | Quotes & News - Moomoo
AbCellera: Q3 Hot Flashes Data Drop Aside, This Stock Is A Difficult Sell (NASDAQ:ABCL) - Seeking Alpha
Q3 2025 Abcellera Biologics Inc Earnings Call Transcript - GuruFocus
AbCellera Biologics Hits Day Low of $5.50 Amid Price Pressure - Markets Mojo
AbCellera Appoints Dr. Victor Sandor to its Board of Directors - BioSpace
A Look At AbCellera Biologics (ABCL) Valuation After ABCL635 Progress And Strong Q1 Results - Yahoo Finance
AbCellera’s Shift To Proprietary Drugs Puts ABCL635 And Governance In Focus - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
AbCellera Biologics Adds Victor Sandor to Board - The Globe and Mail
AbCellera appoints Victor Sandor to board of directors - Investing.com UK
AbCellera appoints Victor Sandor to board of directors By Investing.com - Investing.com South Africa
AbCellera Biologics bets on hot flash antibody as pipeline pivot gains steam - MSN
AbCellera appoints Victor Sandor to its Board - TradingView
AbCellera (NASDAQ: ABCL) appoints oncology leader Dr. Victor Sandor as independent director - Stock Titan
Abcellera Biologics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Abcellera Biologics Inc (ABCL) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):